Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
This list of potential positions covers Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.
Story appears to be empty
Biofrontera AG (BFRA)
The company has return on total asset (ROA) of (10.51) % which means that it has lost $10.51 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (124.08) %, meaning that it created substantial loss on money invested by shareholders. Biofrontera's management efficiency ratios could be used to measure how well Biofrontera manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Micro-Cap' category with a current market capitalization of 80.19 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Biofrontera's market, we take the total number of its shares issued and multiply it by Biofrontera's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
BeyondSpring (BYSI)
The company has return on total asset (ROA) of (0.3869) % which means that it has lost $0.3869 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.1048) %, meaning that it created substantial loss on money invested by shareholders. BeyondSpring's management efficiency ratios could be used to measure how well BeyondSpring manages its routine affairs as well as how well it operates its assets and liabilities. The BeyondSpring's current Return On Equity is estimated to increase to 5.73, while Return On Tangible Assets are projected to decrease to (0.74). As of now, BeyondSpring's Debt To Assets are increasing as compared to previous years. The BeyondSpring's current Asset Turnover is estimated to increase to 0.03, while Total Assets are projected to decrease to under 43.6 M. The firm currently falls under 'Micro-Cap' category with a current market capitalization of 82.32 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BeyondSpring's market, we take the total number of its shares issued and multiply it by BeyondSpring's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Net Debt
(27.82 Million)
As of now, BeyondSpring's Net Debt is decreasing as compared to previous years.
ImmuCell (ICCC)
The company has return on total asset (ROA) of (0.0736) % which means that it has lost $0.0736 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2086) %, meaning that it created substantial loss on money invested by shareholders. ImmuCell's management efficiency ratios could be used to measure how well ImmuCell manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.05. In addition to that, Return On Capital Employed is expected to decline to -0.05. At present, ImmuCell's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 16.9 M, whereas Non Currrent Assets Other are forecasted to decline to about 65.5 K. The company currently falls under 'Micro-Cap' category with a current market capitalization of 38.99 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ImmuCell's market, we take the total number of its shares issued and multiply it by ImmuCell's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. ImmuCell retains a regular Real Value of $7.3 per share. The prevalent price of the firm is $5.03. Our model calculates the value of ImmuCell from evaluating the firm fundamentals such as Current Valuation of 54.7 M, return on asset of -0.0736, and Return On Equity of -0.21 as well as inspecting its technical indicators and probability of bankruptcy. In general, most investors encourage purchasing undervalued assets and exiting overvalued assets since, at some point, asset prices and their ongoing real values will come together.
Cellect Biotechnology (APOP)
The company has return on total asset (ROA) of (42.77) % which means that it has lost $42.77 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (121.25) %, meaning that it created substantial loss on money invested by shareholders. Cellect Biotechnology's management efficiency ratios could be used to measure how well Cellect Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. The entity currently falls under 'Micro-Cap' category with a current market capitalization of 51.61 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cellect Biotechnology's market, we take the total number of its shares issued and multiply it by Cellect Biotechnology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Kazia Therapeutics Ltd (KZIA)
The company has return on total asset (ROA) of (0.4642) % which means that it has lost $0.4642 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8637) %, meaning that it created substantial loss on money invested by shareholders. Kazia Therapeutics' management efficiency ratios could be used to measure how well Kazia Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -2.07. In addition to that, Return On Capital Employed is expected to decline to -1.42. At present, Kazia Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 6.7 M, whereas Non Current Assets Total are forecasted to decline to about 11.4 M. This firm currently falls under 'Nano-Cap' category with a current market capitalization of 9.94 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Kazia Therapeutics's market, we take the total number of its shares issued and multiply it by Kazia Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Kazia Therapeutics is undervalued. Kazia Therapeutics secures a last-minute Real Value of $0.76 per share. The latest price of the firm is $0.4. Our model forecasts the value of Kazia Therapeutics from analyzing the firm fundamentals such as Return On Equity of -1.86, shares owned by institutions of 18.54 %, and Current Valuation of 96.18 M as well as examining its technical indicators and probability of bankruptcy. In general, most investors recommend taking in undervalued stocks and trading overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
Collplant Biotechnologies (CLGN)
The company has return on total asset (ROA) of (0.1306) % which means that it has lost $0.1306 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2316) %, meaning that it created substantial loss on money invested by shareholders. Collplant Biotechnologies' management efficiency ratios could be used to measure how well Collplant Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of April 2024, Return On Tangible Assets is likely to drop to -0.22. In addition to that, Return On Capital Employed is likely to drop to -0.26. At this time, Collplant Biotechnologies' Other Current Assets are very stable compared to the past year. As of the 23rd of April 2024, Intangible Assets is likely to grow to about 265.7 K, while Total Assets are likely to drop about 18.2 M. The entity currently falls under 'Micro-Cap' category with a current market capitalization of 60.25 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Collplant Biotechnologies's market, we take the total number of its shares issued and multiply it by Collplant Biotechnologies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Net Debt
(22.57 Million)
Collplant Biotechnologies reported last year Net Debt of (23.76 Million)
The company has return on total asset (ROA) of (10.51) % which means that it has lost $10.51 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (124.08) %, meaning that it created substantial loss on money invested by shareholders. Biofrontera's management efficiency ratios could be used to measure how well Biofrontera manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Micro-Cap' category with a current market capitalization of 80.19 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Biofrontera's market, we take the total number of its shares issued and multiply it by Biofrontera's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
BeyondSpring (BYSI)
The company has return on total asset (ROA) of (0.3869) % which means that it has lost $0.3869 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.1048) %, meaning that it created substantial loss on money invested by shareholders. BeyondSpring's management efficiency ratios could be used to measure how well BeyondSpring manages its routine affairs as well as how well it operates its assets and liabilities. The BeyondSpring's current Return On Equity is estimated to increase to 5.73, while Return On Tangible Assets are projected to decrease to (0.74). As of now, BeyondSpring's Debt To Assets are increasing as compared to previous years. The BeyondSpring's current Asset Turnover is estimated to increase to 0.03, while Total Assets are projected to decrease to under 43.6 M. The firm currently falls under 'Micro-Cap' category with a current market capitalization of 82.32 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BeyondSpring's market, we take the total number of its shares issued and multiply it by BeyondSpring's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Net Debt
(27.82 Million)
As of now, BeyondSpring's Net Debt is decreasing as compared to previous years.
ImmuCell (ICCC)
The company has return on total asset (ROA) of (0.0736) % which means that it has lost $0.0736 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2086) %, meaning that it created substantial loss on money invested by shareholders. ImmuCell's management efficiency ratios could be used to measure how well ImmuCell manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.05. In addition to that, Return On Capital Employed is expected to decline to -0.05. At present, ImmuCell's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 16.9 M, whereas Non Currrent Assets Other are forecasted to decline to about 65.5 K. The company currently falls under 'Micro-Cap' category with a current market capitalization of 38.99 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ImmuCell's market, we take the total number of its shares issued and multiply it by ImmuCell's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. ImmuCell retains a regular Real Value of $7.3 per share. The prevalent price of the firm is $5.03. Our model calculates the value of ImmuCell from evaluating the firm fundamentals such as Current Valuation of 54.7 M, return on asset of -0.0736, and Return On Equity of -0.21 as well as inspecting its technical indicators and probability of bankruptcy. In general, most investors encourage purchasing undervalued assets and exiting overvalued assets since, at some point, asset prices and their ongoing real values will come together.
Cellect Biotechnology (APOP)
The company has return on total asset (ROA) of (42.77) % which means that it has lost $42.77 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (121.25) %, meaning that it created substantial loss on money invested by shareholders. Cellect Biotechnology's management efficiency ratios could be used to measure how well Cellect Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. The entity currently falls under 'Micro-Cap' category with a current market capitalization of 51.61 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cellect Biotechnology's market, we take the total number of its shares issued and multiply it by Cellect Biotechnology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Kazia Therapeutics Ltd (KZIA)
The company has return on total asset (ROA) of (0.4642) % which means that it has lost $0.4642 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8637) %, meaning that it created substantial loss on money invested by shareholders. Kazia Therapeutics' management efficiency ratios could be used to measure how well Kazia Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -2.07. In addition to that, Return On Capital Employed is expected to decline to -1.42. At present, Kazia Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 6.7 M, whereas Non Current Assets Total are forecasted to decline to about 11.4 M. This firm currently falls under 'Nano-Cap' category with a current market capitalization of 9.94 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Kazia Therapeutics's market, we take the total number of its shares issued and multiply it by Kazia Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Kazia Therapeutics is undervalued. Kazia Therapeutics secures a last-minute Real Value of $0.76 per share. The latest price of the firm is $0.4. Our model forecasts the value of Kazia Therapeutics from analyzing the firm fundamentals such as Return On Equity of -1.86, shares owned by institutions of 18.54 %, and Current Valuation of 96.18 M as well as examining its technical indicators and probability of bankruptcy. In general, most investors recommend taking in undervalued stocks and trading overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
Collplant Biotechnologies (CLGN)
The company has return on total asset (ROA) of (0.1306) % which means that it has lost $0.1306 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2316) %, meaning that it created substantial loss on money invested by shareholders. Collplant Biotechnologies' management efficiency ratios could be used to measure how well Collplant Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of April 2024, Return On Tangible Assets is likely to drop to -0.22. In addition to that, Return On Capital Employed is likely to drop to -0.26. At this time, Collplant Biotechnologies' Other Current Assets are very stable compared to the past year. As of the 23rd of April 2024, Intangible Assets is likely to grow to about 265.7 K, while Total Assets are likely to drop about 18.2 M. The entity currently falls under 'Micro-Cap' category with a current market capitalization of 60.25 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Collplant Biotechnologies's market, we take the total number of its shares issued and multiply it by Collplant Biotechnologies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Net Debt
(22.57 Million)
Collplant Biotechnologies reported last year Net Debt of (23.76 Million)
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Please refer to our Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Did you try this?
Run Volatility Analysis Now
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any private could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
